Madrigal Pharmaceuticals, Inc. - Common Stock —— 季度资产负债表 (NASDAQ:MDGL) | MetaTrader

展开完整图表完整图表

新闻

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?

ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms

ALT Pemvidutide Explained: What Makes It Different in MASH